Literature DB >> 8913488

In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.

C C Kuo1, L A Jackson, A Lee, J T Grayston.   

Abstract

The in vitro susceptibilities of Chlamydia pneumoniae isolates to macrolide, tetracycline, and quinolone antibiotics were determined. Tetracycline, clarithromycin, and erythromycin had the lowest MICs in the first cell culture passage. Azithromycin required the lowest concentration for complete inhibition of inclusion formation on the second pass into antibiotic-free medium, likely reflecting its high intracellular concentrations.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8913488      PMCID： PMC163599     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics.

Authors:  M A Cooper; D Baldwin; R S Matthews; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

2.  In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.

Authors:  Y Niki; M Kimura; N Miyashita; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

3.  Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.

Authors:  K Nakata; Y Okazaki; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

4.  Infection with Chlamydia pneumoniae in Brooklyn.

Authors:  K Chirgwin; P M Roblin; M Gelling; M R Hammerschlag; J Schachter
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

Review 6.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  An epidemic of infections due to Chlamydia pneumoniae in military conscripts.

Authors:  M R Ekman; J T Grayston; R Visakorpi; M Kleemola; C C Kuo; P Saikku
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

9.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

10.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191
View more
  9 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis.

Authors:  J D Rutherford
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Chlamydia pneumoniae resists antibiotics in lymphocytes.

Authors:  Hiroyuki Yamaguchi; Herman Friedman; Mayumi Yamamoto; Keigo Yasuda; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

3.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  High frequency of Chlamydia pneumoniae and risk factors in children with acute respiratory infection.

Authors:  Matheus Silva Alves; Marilha da Silva Cariolano; Hivylla Lorrana Dos Santos Ferreira; Elen Sousa de Abreu Silva; Karen Karollynny Pereira Felipe; Silvio Gomes Monteiro; Eduardo Martins de Sousa; Afonso Gomes Abreu; Lee Ann Campbell; Michael E Rosenfeld; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata; Gisele Medeiros Bastos; Ilana Cristina de Paula Abreu Silva; Lidio Gonçalves Lima-Neto
Journal:  Braz J Microbiol       Date:  2020-01-30       Impact factor: 2.476

5.  Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.

Authors:  K Wolf; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease.

Authors:  Raúl Altman; Jorge Rouvier; Alejandra Scazziota; Claudio Gonzalez
Journal:  Inflammation       Date:  2002-02       Impact factor: 4.092

7.  Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.

Authors:  Geneviève Goy; Gilbert Greub
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

8.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

9.  Risk factors in coronary atherosclerosis athero-inflammation: the meeting point.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2003-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.